Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson’s disease

• Published in: Scientific reports 2024-04, Vol.14 (1), p.8581-8581, Article 8581
• Main Authors: Guo, Chunying, Wang, Ting, Huang, Haiyan, Wang, Xiaolu, Jiang, Yugui, Li, Jinan
• Format: Article
• Language: English
• Subjects: 631/378; 692/617; alpha-Synuclein; Animal models; Animals; Blood-brain barrier; Brain; Disease Models, Animal; DNA-Binding Proteins - metabolism; Dopamine; Dopamine receptors; Dopaminergic neuron; Dopaminergic Neurons - pathology; Drug development; Humanities and Social Sciences; Lewy bodies; Mice; Movement disorders; MPTP; multidisciplinary; Neostriatum; Neurodegeneration; Neurodegenerative diseases; Neurodegenerative Diseases - metabolism; Okadaic acid; Parkinson Disease - metabolism; Parkinson's disease; Phosphorylation; Plasmin; Plasminogen; Plasminogen - metabolism; Proteolysis; Science; Science (multidisciplinary); Serine Proteases; Substantia nigra; Synuclein; Tau; Tau protein; tau Proteins - metabolism; TDP-43; Tyrosine 3-monooxygenase; α-syn
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-59090-8

Parkinson's disease (PD) is the second most frequently diagnosed neurodegenerative disease, and it is characterized by the intracellular and extracellular accumulation of α-synuclein (α-syn) and Tau, which are major components of cytosolic protein inclusions called Lewy bodies, in the brain. Currently, there is a lack of effective methods that preventing PD progression. It has been suggested that the plasminogen activation system, which is a major extracellular proteolysis system, is involved in PD pathogenesis. We investigated the functional roles of plasminogen in vitro in an okadaic acid-induced Tau hyperphosphorylation NSC34 cell model, ex vivo using brains from normal controls and methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, and in vivo in a widely used MPTP-induced PD mouse model and an α-syn overexpression mouse model. The in vitro, ex vivo and in vivo results showed that the administered plasminogen crossed the blood‒brain barrier (BBB), entered cells, and migrated to the nucleus, increased plasmin activity intracellularly, bound to α-syn through lysine binding sites, significantly promoted α-syn, Tau and TDP-43 clearance intracellularly and even intranuclearly in the brain, decreased dopaminergic neurodegeneration and increased the tyrosine hydroxylase levels in the substantia nigra and striatum, and improved motor function in PD mouse models. These findings indicate that plasminogen plays a wide range of pivotal protective roles in PD and therefore may be a promising drug candidate for PD treatment.